Navigation Links
Verenium Corporation To Announce Third Quarter 2012 Financial Results
Date:11/1/2012

SAN DIEGO, Nov. 1, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it will release 2012 third quarter financial results on Thursday, November 8, 2012 after market close. In conjunction with the release, the Company will host a conference call with live webcast on Thursday, November 8, 2012 at 5:00 p.m. ET.

(Logo: http://photos.prnewswire.com/prnh/20120924/MM79973LOGO)

The call may be accessed by dialing (877) 755-7422 (domestic) or (678) 894-3067 (international) five minutes prior to start time and providing the passcode 55940538.  A link to the live webcast may be accessed by visiting the "Investors" section of the Company's website at http://ir.verenium.com/.  A replay of the event will be available on the Company's website approximately two hours after the call and will be archived for 30 days.

About Verenium
Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

Forward-Looking Statements
Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's technology, products and product candidates and product pipeline, lines of business, operations (including Verenium's ability to successfully negotiate and enter into fut
'/>"/>

SOURCE Verenium Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
2. Verenium to Present at Baird Clean Technology Conference
3. First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration
4. Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results
5. Verenium Corporation To Announce First Quarter 2012 Financial Results
6. Verenium Corporation Named One Of The 2012 Best Places to Work in San Diego
7. Verenium Corporation And Alexandria Real Estate Equities, Inc. Celebrate The Grand Opening Of A New State-of-the-art Biotechnology Facility
8. Verenium Announces EPA Authorization To Market Its Next-Generation Enzyme Breaker For Hydraulic Fracturing
9. Verenium Corporation To Announce Second Quarter 2012 Financial Results
10. Verenium Reports Financial Results For The Second Quarter And Six Months Ended June 30, 2012
11. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)...  China Cord Blood Corporation (NYSE: CO ... financial results for the first quarter of fiscal year ... in the US.  The Company will ... Friday, August 29, 2014 to discuss its financial performance ... developments, followed by a question and answer session.  Interested ...
(Date:8/21/2014)... Bulgaria (PRWEB) August 21, 2014 ... released today by Ontotext . Now the ... semantic analysis of structured and unstructured data is available ... the cost of enterprise technology. Organizations that do not ... for data management can use S4 since there is ...
(Date:8/21/2014)... August 21, 2014 On Wednesday of last ... to use Redox Signaling molecules, became available for purchase in ... , "The way that RENU 28 works is, if you ... down of the rate of cellular renewal within your body. ... increasing of that rate of cellular renewal. What RENU 28 ...
(Date:8/20/2014)... American Indians largely were wiped out by diseases such ... to the New World by European explorers., One report ... in the Americas shortly before Europeans arrived, and roughly ... But new research led by anthropological geneticists Anne Stone ... University of Tubingen in Germany indicates the diagnosis of ...
Breaking Biology Technology:China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4RENU 28 Skin Care Now Available in Australia and New Zealand 2Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3
... Hospitals in Western Pennsylvania Earn Designation, PITTSBURGH, ... named Allegheny General Hospital, UPMC Presbyterian Shadyside and ... Rare Cancers., Complex and rare cancers comprise ... making it difficult for patients to locate or,research ...
... has announced,development of a chemically synthesized vaccine specific ... patented Replikins(TM) technology.,When the vaccine was administered orally ... Taura virus. The specificity of the protective,effect was ... active,regions in the vaccine, and as a result ...
... Prescribing of Copaxone over an Interferon-Beta Therapy, According to a ... ... Resources, WALTHAM, Mass., March 11 Decision Resources, one ... issues, finds that Teva Pharmaceutical,s Copaxone has the,greatest patient share among ...
Cached Biology Technology:Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 2Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 3Replikins Oral Vaccine Synthesized in 7 Days Protects 91% of Shrimp Against a Lethal Virus 2Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis 2Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis 3
(Date:8/21/2014)... Researchers from North Carolina State University have developed a ... The model has applications for creating new materials as ... , "Our new technique allows us to model much ... so much more quickly," says Nan Li, lead author ... student in NC State,s Department of Materials Science and ...
(Date:8/20/2014)... Institute (HCI) at the University of Utah have identified ... BCR-ABL, the unregulated enzyme driving the blood cancer chronic ... nearly 6,000 new cases of CML will be diagnosed ... kinase inhibitors (TKIs), target BCR-ABL and are effective at ... control it in a way that allows patients to ...
(Date:8/20/2014)... fires are visible in in this image of the ... of these were most likely intentionally set in order ... a forest or stand of trees where the land ... deforestation include conversion of forestland to farms, ranches, or ... dark green of the Amazon Rainforest in the middle ...
Breaking Biology News(10 mins):Researchers develop models to study polyelectrolytes, including DNA and RNA 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... Ind. - Face-to-face workplace interactions may be the best ... organ donors, according to new research from Purdue University. ... learn about health and wellness issues, but how information ... for sensitive health topics such as organ donation," said ...
... Boston University biology professor Richard Primack, graduate student ... analysis of the changing arrival dates of migratory birds ... Thoreau from the 1850,s. This research builds on earlier ... Concord respond rapidly to temperature and are now flowering ...
... Coulter, Ph.D., a neuroscientist at The Children,s Hospital ... Award for Basic Science from the American Epilepsy ... to epilepsy research on Monday, Dec. 6 at ... the most prestigious prizes for research in epilepsy, ...
Cached Biology News:Study: Personal contacts at work help people better understand organ donation 2Study: Personal contacts at work help people better understand organ donation 3Epilepsy researcher at the Children's Hospital of Philadelphia receives scientific prize 2
HOXC11 Antibody...
Anti-NeuroD 6 Immunogen: Synthetic peptide. Available Date: 36708...
HOXC11 Antibody...
Anti-MMP-14, catalytic domain, clone LEM-2/15.8 Immunogen: Synthetic peptide: amino acid sequence 218-233 within the catalytic domain Available Date: 38579...
Biology Products: